Evidence-based medicine: Comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate

BJU International

Volumn 107, Issue 8, 2011, Pages 1200-1208

  González, Santiago Vilar ^a   Pijuan, Xavier Maldonado ^b  

^a Instituto de Medicina Oncologica y Molecular de Asturias   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

androgen deprivation; drug class effect; evidence based medicine; LHRH analogues; prostate carcinoma

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; MICROSPHERE; NILUTAMIDE; TRIPTORELIN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 79954551025     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09827.x     Document Type: Article

References (79)

1. Evidence-based medicine working group. Evidence-based medicine: a new approach to teaching of medicine. JAMA 1992; 268: 2420-5
2. Evans CP, Fleshner N, Fitzpatrick JM, Zlotta AR,. An evidence-based approach to understanding the pharmacological class effects in the management of prostatic diseases. Br J Urol 2005; 95: 743-9 (Pubitemid 40547199)
3. Scottish Intercollegiate Guidelines Network. A Guideline Developer's Handbook. Edinburgh: Scottish Intercollegiate Guidelines Network, 2001: update May 2004
4. Akaza H,. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer. Br J Urol 2004; 93: 42-6 (Pubitemid 38112961)
5. Horwitz EM, Bae K, Hanks GE, et al,. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: a Phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 1-8
6. Roach M III, Bae K, Speight J, et al,. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26: 585-91 (Pubitemid 351264352)
7. Bolla M, Collette L, Blank L, et al,. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-8 (Pubitemid 34786197)
8. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90 (Pubitemid 40470408)
9. Messing EM, Manola J, Yoo J, et al,. Immediate versus deferred androgen deprivation treatment in patients with node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9 (Pubitemid 43779173)
10. Roach M 3rd, Lu J, Pilepich MV, et al,. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000; 47: 617-7
11. The Cochrane Collaboration, Kumar S, Shelley M, Harrison C, Coles B, Wilt T, Mason M,. Neo-Adjuvant and Adjuvant Hormone Therapy for Localized and Locally Advanced Prostate Cancer (Review). Chichester: Cochrane Library (Wiley), 2009
12. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M,. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49: 947-56 (Pubitemid 32184601)
13. Denham JW, Steigler A, Lamb DS, et al,. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol 2005; 6: 841-50 (Pubitemid 41614795)
14. Crook J, Ludgate C, Malone S, et al,. Report of a multicenter Canadian phase III trial of 3 months vs 8 months neoadjuvant androgen before standard dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 15-23 (Pubitemid 39165464)
15. Roach M III, Izaguirre A,. Goserelin acetate in combination with radiotherapy for prostate cancer. Expert Opin Pharmacother 2007; 8: 257-64 (Pubitemid 46206626)
16. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW,. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-7 (Pubitemid 39079668)
17. Lawton CA, DeSilvio M, Roach M III, et al,. An update of the phase III trial comparing whole pelvis to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: update analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646-55 (Pubitemid 47418390)
18. Bolla M, de Reijke TM, Van Tienhoven G, et al,. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27
19. Ganswindt U, Paulsen F, Anastasiadis AG, Stenzd A, Bamberg M, Belka C,. 70 Gy or more: which dose for which prostate cancer? J Cancer Res Clin Oncol 2005; 131: 407-19 (Pubitemid 40905018)
20. D'Amico AV, Denham JW, Crook J, et al,. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-5 (Pubitemid 46999213)
21. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD,. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009; 35: 917
22. Bria E, Cuppone F, Giannarelli D, et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Cancer 2009; 115: 3446-56
23. Crook J, Ludgate C, Malone S, et al,. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73: 327-33
24. D'Amico AV,. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer. J Clin Oncol 2007; 25: 8-9 (Pubitemid 350003044)
25. Seidenfeld J, Samson DJ, Hasselblad V, et al,. Single-therapy androgen suppression in men with advanced prostate cancer, a systematic review and meta-analysis. Ann Intern Med 2000; 132: 566-77 (Pubitemid 30171897)
26. The Cochrane Collaboration, Wilt T, Nair B, MacDonald R, Rutks I,. Early Versus Deferred Androgen Suppression in the Treatment of Advanced Prostatic Cancer (Review). Chichester: Cochrane Library (Wiley), 2009
27. D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW,. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 2008; 26: 2979-83
28. The Cochrane Database of Systematic Reviews, Schmitt B, Bennett C, Seidenfeld J, Wilt T,. Maximum Androgen Blockade for Advanced Prostate Cancer. Chichester: Cochrane Library (Wiley), 2009
29. Prostate Cancer Triallists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-8
30. Samson DJ, Seidenfed J, Schmitt B, et al,. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 361-76 (Pubitemid 34787603)
31. Caubet JF, Tosteson TD, Dong EW, et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 71-8 (Pubitemid 27043101)
32. Bayoumi AM, Brown AD, Garber AM,. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000; 92: 1731-9
33. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD,. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis 1999; 2: 4-8 (Pubitemid 29096321)
34. Klotz L, Schellhammer P,. Combined androgen blockade: the case for bicalutamide. Clin Prostate Cancer 2005; 3: 215-19 (Pubitemid 40770199)
35. Schellhammer PF, Sharifi R, Block NL, et al,. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 1997; 50: 330-6 (Pubitemid 27428107)
36. Sarosdy MF, Schellhammer PF, Sharifi R, et al,. Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology 1998; 52: 82-8 (Pubitemid 28317934)
37. Jani AB, Shoushtari A, Feinsten JM,. Role of androgen ablation with low-dose-rate brachytherapy in the treatment of prostate cancer. Clin Drug Investig 2006; 26: 723-31 (Pubitemid 44901701)
38. Calais da Silva FEC, Bono AV, Whelan P, et al,. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the south European uroncological group. Eur Urol 2009 [Epub ahead of print]
39. Wright JL, Higano CS, Lin DW,. Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am 2006; 33: 167-79
40. Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galeti T, Tunns U,. The role of intermittent androgen deprivation in prostate cancer. Br J Urol 2007; 100: 738-43 (Pubitemid 47360177)
41. Lu-Yao GL, Albertsen PC, Moore DF, et al,. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-81 (Pubitemid 351969301)
42. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC,. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. Br J Urol 2003; 92: 226-31 (Pubitemid 36966582)
43. Fujii Y, Yonese J, Kawakami S, Yamamoto S, Okubo Y, Fukui I,. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer. Br J Urol 2008; 101: 1096-100 (Pubitemid 351502651)
44. Oefelein MG, Cornum R,. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 726-9 (Pubitemid 30637611)
45. Smith MR,. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res 2007; 13: 241-5 (Pubitemid 46121875)
46. Yri OE, Bjoro T, Fossa SD,. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006; 49: 54-8 (Pubitemid 41789955)
47. Abbou CC, Lucas C, Leblanc V,. Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprorelin and triptorelin in patients with metastatic prostate cancer. Prog Urol 1997; 7: 984-95 (Pubitemid 127525587)
48. Kuhn JM, Abourachid H, Brucher P, et al. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. Eur Urol 1997; 32: 397-403 (Pubitemid 27501035)
49. Tanaka N, Fujimoto K, Hirao Y, Shimizu K, Tsujimoto S, Samma S,. Endocrine response to a single injection of goserelin 3.6 mg or leuprolide 3.75 mg in men with prostate cancer. Arch Androl 2007; 53: 87-90 (Pubitemid 46643408)
50. Morote J, Orsola A, Planas J, et al,. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 1290-5 (Pubitemid 47368393)
51. Perachino M, Cavalli V, Bravi F,. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2009; 105: 648-51
52. Byar DP, Corle DK,. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies. NCI Monogr 1988; 7: 165-70
53. Kaisary AV, Tyrrell CJ, Peeling WB,. Griffiths K, on behalf of Study Group. Comparison of LHRH analogue (Zoladex) with orchidectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-8
54. Vogelzang NJ, Chodak GW, Soloway MS, et al,. Goserelin versus orchidectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995; 46: 220-6
55. Osborne DR, Moffat LEF, Kaisary A, Rees DLP, Weaver JP,. A comparison of Zoladex, cyproterone acetate and stilboestrol in the treatment of patients with advanced prostatic cancer. Recent Advances in Urological Cancers Diagnosis and Treatment. Paris 27-29 June 1990: 53-55.
56. Thorpe CS, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ,. A prospective, randomised study to compare gosereline acetate (Zoladex®) versus cyproterone acetate (Cyprostat®) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 1996; 29: 47-54 (Pubitemid 26009294)
57. Waymont B, Lynch TH, Dunn JA, et al,. Phase III randomised study of Zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992; 69: 614-20
58. de Voogt HJ, Studer U, Schroder FH, Klijn JG, De Pauw M, Sylvester R,. Maximun androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. EORTC Genito-Urinary Tract Cancer Cooperative Group. EUR Urol 1998; 33: 152-8 (Pubitemid 28073757)
59. Bruun E, Frimodt-Moller C,. The effect of buserelin versus conventional antiandrogenic treatment in patients with T2-4NXM1 prostatic cancer. A prospective, randomized multicentre phase III trial. The 'Danish Buserelin Study Group'. Scand J Urol Nephrol 1996; 30: 291-7 (Pubitemid 26332448)
60. Huben RP, Murphy GP,. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 1988; 62: 1881-7 (Pubitemid 18261808)
61. Klioze SS, Miller MF, Spiro TP,. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients. Am J Clin Oncol 1988; 11 (Suppl. 2): S176-82 (Pubitemid 19112745)
62. Parmar H, Edwards L, Phillips RH, Allen L, Lightman SL,. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 1987; 59: 248-54 (Pubitemid 17037977)
63. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281-6
64. Askew B, Gampe RT JR, Stanley TB, Faggart JL, Wilson EM,. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007; 282: 25801-16 (Pubitemid 47372778)
65. Schally AV, Redding TW, Paz-Bouza JI, Comaru-Schally AM, Mathe G,. Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents. Prog Clin Biol Res 1987; 243A: 173-97
66. Watanabe T, Yamada N, Yoshida Y, Yamamoto O,. A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate. J Cutan Pathol 2009; Epub ahead of print
67. Murthy GG, Modesto RR,. Effects of luteinizing hormone releasing hormone and thyrotrophin releasing hormone on rabbit adipose tissue. J Endocrinol 1974; 62: 639
68. Yasukawa K, Sawamura D, Sugawara H, Kato N,. Leuprorelin acetate granulomas: case reports and review of the literature. Br J Dermatol 2005; 152: 1045-7 (Pubitemid 40704951)
69. Shiota M, Tokuda N, Kanou T, Yamasaki H,. Injection-site granulomas due to the administration of leuprorelin acetate for the treatment of prostatic cancer. Fukuoka Igaku Zasshi 2007; 98: 301-4
70. Ouchi T, Koyama T, Miyata N, Sugiura M,. Granuloma caused by subcutaneous injection of leuprorelin acetate product: case report and histopathological findings. J Dermatol 2006; 33: 719-21 (Pubitemid 44536380)
71. Koupparis AJ, Yri OE, Bjoro T, Fossa SD,. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006; 49: 54-8. Eur Urol 2006; 50: 626-627 (Pubitemid 41789955)
72. Vieu C, Arnault JP, Petitpain N, et al,. Granuloma at the injection site of leuprorelin acetate: foreign body reaction to polylactic acid. Ann Dermatol Venereol 2007; 134: 771-3 (Pubitemid 350036995)
73. Shiota M, Tokuda N, Kanou T, Yamasaki H,. Injection-site granulomas resulting from the administration of both leuprorelin acetate and goserelin acetate for the treatment of prostatic cancer. J Nippon Med Sch 2007; 74: 306-8 (Pubitemid 47311978)
74. Daskivich TJ, Oh WK,. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms? Urology 2006; 67: 1084. e15-17
75. Kerle D, Williams G, Ware H, Bloom SR,. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress luteinising hormone and testosterone. Br Med J (Clin Res Ed) 1984; 289: 468-9 (Pubitemid 14011589)
76. Ferran M, Giménez-Arnau A, Toll A, et al,. Depot leuprorelin acetate-induced granulomas manifested as persistent suppurative nodules. Acta Derm Venereol 2006; 86: 453-5 (Pubitemid 44450108)
77. Ogan K, Berger M, Ball R,. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma. J Urol 1998; 160: 497-98 (Pubitemid 29476710)
78. Matsuda T, Hiura Y, Oguchi N, Muguruma K, Murota T, Kawakita M,. Failure of a gonadotropin-releasing hormone analogue to lower serum testosterone in patients with prostate cancer. Urology 2002; 59: 296
79. Dajavan B, Marberger M,. A meta-analysis on the efficacy and tolerability of alpha 1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13 (Pubitemid 29265274)